Sponsor: Bristol Myers Squibb
Sponsor Study ID: CA071-1000
Study Title: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
CTO #: 104150
NCT Number: NCT06764485
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: To compare the efficacy of BMS-986365 vs investigator s choice of therapy. To compare the efficacy of BMS-986365 vs investigator s choice of therapy. Part 1 only: to inform the dose of BMS-986365 to continue in part 2 of the study. To further assess the efficacy of BMS-986365 vs investigator s choice of therapy. To investigate the effect on PROs in this study population when treated with BMS-986365 vs investigator's choice of therapy.